
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Idiopathic thrombocytopenic purpura surgery
Introduction
Overview
Overview
Surgery
Surgery
Splenectomy
Splenectomy offers a 2nd line treatment for those who fail steroids. The criteria for surgery are severe thrombocytopenia (<10,000), high risk of bleeding or the requirement of frequent steroids/IVIgG/anti-D treatment to maintain an adequate platelet count. Of the ~15% of children with persistent thrombocytopenia bleeding symptoms are uncommon and splenectomy is rarely required. However splenectomy is an effective treatment option for children with severe / symptomatic thrombocytopenia with a CR of ~75%. Because of the risk for overwhelming sepsis after splenectomy it should be deferred until after 5 years of age. Remember to give immunizations before splenectomy and perioperative antibiotics. Response to IV-IgG often predicts a response to splenectomy (increasing the platelet count to >50,000 with IgG means a >90% RR to splenectomy).[1]
Splenectomy is safe and effective in ~80% of patients with refractory HIV-related thrombocytopenia and treated with interferon (IFN) may be effective in refractory cases of patients coinfected with HCV. A decrease in platelets in HIV can arise secondary to both HCV and hepatitis B (HBV).[2]
References
References
- β Ghanima W, Godeau B, Cines DB, Bussel JB (August 2012). “How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment”. Blood. 120 (5): 960β9. doi:10.1182/blood-2011-12-309153. PMIDΒ 22740443.
- β Schifferli A, KΓΌhne T (January 2013). “Chronic immune thrombocytopenia in children: who needs splenectomy?”. Semin. Hematol. 50 Suppl 1: S58β62. doi:10.1053/j.seminhematol.2013.03.010. PMIDΒ 23664519.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
